SCHEMBL5545488

SCHEMBL5545488

CCOC(=O)CCCCCc1ccc(O)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP4Z1 Q86W10 2/20 0.59
CYP4F2 P78329 2/20 0.57
CYP4A11 Q02928 2/20 0.57
ACHE P22303 3/20 0.56
ESR1 P03372 2/20 0.56
ADRA2A P08913 2/20 0.56
ADORA3 P0DMS8 2/20 0.56
TACR2 P21452 2/20 0.56
SLC6A2 P23975 2/20 0.56
SLC6A4 P31645 2/20 0.56
SLC6A3 Q01959 2/20 0.56
KDM4E B2RXH2 1/20 0.56
ALDH1A1 P00352 1/20 0.56
LMNA P02545 1/20 0.56
SHBG P04278 1/20 0.56
TP53 P04637 1/20 0.56
CYP3A4 P08684 1/20 0.56
HSPD1 P10809 1/20 0.56
ADRB3 P13945 1/20 0.56
HTR2C P28335 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11615189 1.00 CYP4Z1 (0.59) CYP4Z1CYP4F2CYP4A11ACHEESR1
SCHEMBL5544355 1.00 CYP4Z1 (0.59) CYP4Z1CYP4F2CYP4A11ACHEESR1
SCHEMBL5542112 0.98 CYP4Z1 (0.60) CYP4Z1CYP4F2CYP4A11ACHEESR1
SCHEMBL5050631 0.93 CYP4F2 (0.60) CYP4Z1CYP4F2CYP4A11ACHEESR1
SCHEMBL9671800 0.93 CYP4Z1 (0.65) CYP4Z1CYP4F2CYP4A11ALDH1A1CYP3A4
SCHEMBL6204525 0.89 CYP4Z1 (0.60) CYP4Z1CYP4F2CYP4A11ALDH1A1CYP3A4
SCHEMBL765853 0.89 CYP4Z1 (0.60) CYP4Z1CYP4F2CYP4A11ALDH1A1CYP3A4
SCHEMBL10289901 0.89 CYP4Z1 (0.60) CYP4Z1CYP4F2CYP4A11ALDH1A1CYP3A4
SCHEMBL10929511 0.89 CYP4Z1 (0.60) CYP4Z1CYP4F2CYP4A11ACHEESR1
SCHEMBL5545484 0.87 CYP4Z1 (0.59) CYP4Z1CYP4F2CYP4A11ALDH1A1CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7304062-B2 Peroxisome proliferator activated receptor alpha agonists ELI LILLY AND COMPANY (US) 2007-12-04 US disclosed
US-7304062-B2 Peroxisome proliferator activated receptor alpha agonists ELI LILLY AND COMPANY (US) 2007-12-04 US disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
US-4082850-A TOPICAL APPLICATION OF A 6,11-DIHYDROBENZ(B,E)OXEPIN-ALKANOIC ACID OR DERIVATIVES THEREOF AMERICAN HOECHST CORPORATION (US) 1978-04-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 CYP4Z1 1854/4885CYP4F2 954/4885CYP4A11 1804/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.